Top Story

Addition of head, neck exam to lung cancer screening may increase early detection of HNSCC

January 23, 2015

The prevalence of head and neck squamous cell carcinoma in current and former smokers may justify adding head and neck exams to routine lung cancer screening for high-risk individuals, according to study results.

Doing so could increase early detection of and improve outcomes associated with head and neck squamous cell carcinoma (HNSCC), researchers wrote.

Daniel Kaemmerer In the Journals

Somatostatin receptors serve as viable markers in bronchopulmonary neuroendocrine neoplasms

January 23, 2015
Somatostatin receptors may have utility as diagnostic, prognostic and therapeutic markers of bronchopulmonary neuroendocrine neoplasms, according to research published…
In the Journals

Rotating night shifts raised mortality risk for US female nurses

January 22, 2015
Female nurses who reported working rotating night shifts for 5 years or longer had a modest increase in the risk in all-cause and CVD-related mortality, according to…
Breaking News

Trial of Opdivo in NSCLC ends 2 years early due to favorable outcomes

January 13, 2015
A randomized phase 3 trial designed to evaluate the novel agent nivolumab in previously treated patients with advanced, squamous cell non–small cell lung cancer…
CME CNE
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
CME CNE
Low Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 1 Low Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain MDS…
More »

Filter By:

Brenda Diergaarde, PhD In the Journals

Addition of head, neck exam to lung cancer screening may increase early detection of HNSCC

January 23, 2015
The prevalence of head and neck squamous cell carcinoma in current and former smokers may justify adding head and neck exams to routine lung cancer…
Daniel Kaemmerer In the Journals

Somatostatin receptors serve as viable markers in bronchopulmonary neuroendocrine neoplasms

January 23, 2015
Somatostatin receptors may have utility as diagnostic, prognostic and therapeutic markers of bronchopulmonary neuroendocrine neoplasms, according to…
In the Journals

Rotating night shifts raised mortality risk for US female nurses

January 22, 2015
Female nurses who reported working rotating night shifts for 5 years or longer had a modest increase in the risk in all-cause and CVD-related…
Breaking News

Trial of Opdivo in NSCLC ends 2 years early due to favorable outcomes

January 13, 2015
A randomized phase 3 trial designed to evaluate the novel agent nivolumab in previously treated patients with advanced, squamous cell non–small…
In the Journals

Prophylactic cranial irradiation effective for stage IIIA-N2 NSCLC

January 6, 2015
Prophylactic cranial radiation significantly extended DFS compared with observation in patients with fully resected stage IIIA-N2 non–small…
In the Journals

Carboplatin–paclitaxel combination shows promise for rare form of thymus cancer

December 29, 2014
The combination of carboplatin and paclitaxel compared favorably with standard anthracycline-based chemotherapy in the treatment of thymic carcinoma…
Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease In the Journals

Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease

December 17, 2014
An analysis of genomic rearrangements detected by a diagnostic lineage test helped determine whether multiple non–small cell lung cancer tumors…
FDA approvals

FDA expands approval of Cyramza to include aggressive NSCLC

December 17, 2014
The FDA expanded the approved use of ramucirumab to include use in combination with docetaxel for second-line treatment of patients with metastatic…
In the Journals

Second-line SBRT plus erlotinib extended survival in advanced NSCLC

December 15, 2014
Treatment with stereotactic body radiation therapy and erlotinib appeared highly effective in patients with metastatic stage IV non–small cell…
Richard Pazdur, MD FDA approvals

FDA expands approval of ramucirumab to treat aggressive NSCLC

December 12, 2014
The FDA today announced the expanded approval of ramucirumab in the treatment of patients with metastatic non–small cell lung…
More Headlines »